key: cord-0754159-zv8jfwrg authors: Cheng, Yangyang; Cao, Xinxi; Cao, Zhi; Xu, Chenjie; Sun, Li; Gao, Ying; Wang, Yuan; Li, Shu; Wu, Cunjin; Li, Xin; Wang, Yaogang; Leng, Sean Xiao title: Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality date: 2020-07-16 journal: Ageing Res Rev DOI: 10.1016/j.arr.2020.101124 sha: fa8b3c172035dae58e0af964460e3623c0af72a4 doc_id: 754159 cord_uid: zv8jfwrg BACKGROUND: Influenza vaccination is a simple strategy recommended for the prevention of influenza infection and its complications. The meta-analysis aimed to provide current supportive evidence for the breadth and validity of the observed protective effects of influenza vaccination on cardiovascular and respiratory adverse outcomes and all-cause mortality in older adults and in general adult population. METHODS: We searched PubMed, Embase, Web of Science, and the Cochrane Library to identify all published studies comparing influenza vaccination with placebo from the database inception to November 11, 2018. These included studies reporting the associations of influenza vaccination with the risk of aforementioned adverse outcomes. RESULTS: The pooled adjusted relative risks among influenza-vaccinated people relative to unvaccinated people for the outcomes of interest were 0.74 (95% confidence interval [CI] = 0.70-0.78) for cardiovascular diseases (63 studies), 0.82 (95% CI = 0.75-0.91) for respiratory diseases (29 studies), and 0.57 (95% CI = 0.51-0.63) for all-cause mortality (43 studies). We performed subgroup analysis of age, gender, sex, and region/country and found that these protective effects were evident in the general adult population and particularly robust in older adults and in those with pre-existing specific diseases. CONCLUSION: Influenza vaccine is associated with a significant risk reduction of cardiovascular and respiratory adverse outcomes as well as all-cause mortality. Such a preventative measure can benefit the general population as well as those in old age and with specific diseases. Despite significant progress in the advancement of medical and surgical treatment and healthcare delivery, influenza remains to be a cause of significant morbidity and mortality. According to the World Health Organization (WHO), up to 650,000 people die from influenza infection worldwide each year (Organization) . Influenza also causes tremendous loss of productivity and economic burden. For example, in 2015, influenza-related direct medical costs topped $3.2 billion while lost earnings and productivity for adults reached $8 billion in the US (Putri et al., 2018) . Older adults are particularly vulnerable to influenza infection and its complications. In fact, over 90% influenza-related mortality occur in adults aged 65 years and older (Simonsen et al., 2005; Thompson et al., 2009) . This is likely because of the multifaceted immune system remodeling during aging, leading to immune functional decline in older adults, or immunosenescence (Nikolich-Žugich, 2018) . The aging immune system also manifests a chronic low-grade inflammatory phenotype (CLIP) or inflammaging that has been implicated in the pathogenesis of almost all age-related chronic conditions including those in the cardiovascular and respiratory systems (Chen et al., 2019; Franceschi et al., 2000) . This increased vulnerability to respiratory infections is further demonstrated by the ongoing coronavirus disease 2019 (COVID-19) pandemic as older adults suffer disproportionately high rate of severe COVID-19 disease and deaths (Salje and Tran Kiem, 2020; Zhou et al., 2020) . While the underlying mechanism for this COVID-19 susceptibility is not known at the present time, CLIP or inflammaging is hypothesized to play an important role (Bonafè et al., 2020) . Older adults with chronic diseases are particularly at higher risk for influenza infection and its complications and, in turn, influenza infection may worsen their chronic conditions (Sanei and Wilkinson, 2016) . Influenza vaccination has been approved as a simple protective strategy for reducing influenza and its complications (Grohskopf et al., 2016; Wang et al., 2018) . It is considered the most effective measure for the prevention of influenza. Especially in the elderly, influenza vaccination has been shown to halve the incidence of serological and clinical influenza (in periods of antigenic drift) (Govaert et al., 1994) . Previous studies indicated that influenza vaccination is associated with a significant reduction in respiratory diseases, including influenza and secondary pneumonia (Gross et al., 1995; Nichol et al., 1994; Wang et al., 2002) , exacerbation of chronic lung disease (Nichol et al., 1999) including chronic obstructive pulmonary disease (COPD) (Kopsaftis et al., 2018) and acute episodes of asthma (Vasileiou et al., 2017) . In recent years, growing attention has turned to cardiovascular diseases, as influenza vaccination has been linked to a significant risk reduction for cardiovascular diseases like stroke (Christiansen et al., 2019; Smeeth et al., 2004) , acute coronary syndrome (Phrommintikul et al., 2011; Sung et al., 2014) , heart failure (Christiansen et al., 2019; Vardeny et al., 2016) , and myocardial infarction (Christiansen et al., 2019; Naghavi et al., 2000; Smeeth et al., 2004) . Influenza vaccination is also associated with a significant reduction in mortality in adults aged 65 years and older. In one study after adjusting for age, sex, and risk status, influenza vaccination was found to be associated with a 44% reduction in all-cause mortality (Wang et al., 2007) . However, comprehensive analyses of the data available in the literature that are supportive of protective effects of influenza vaccination beyond influenza prevention in the general population as well as those in old age and with comorbidities are few and far between. Therefore, the objective of this study was to conduct an in-depth synthesis of the available data addressing the breadth and validity of the reported protective effects of influenza vaccination against cardiovascular and respiratory adverse outcomes and all-cause mortality in adults. To this end, we have conducted a meta-analysis of the evidence across existing studies. We searched PubMed, Embase, Web of Science, and the Cochrane Library to identify all published studies comparing influenza vaccination with placebo from the database inception to November 11, 2018 and limited the search to English-language papers. The search used key terms, including influenza, influenza vaccination, cohort, case control and randomized controlled trial (RCT). Our study inclusion criteria were (i) reporting the association between influenza vaccination and cardiovascular, respiratory, and all-cause mortality risk in adults; (ii) comparing an influenza-vaccinated group with an unvaccinated control group; (iii) all RCTs, observational studies, cohort studies (including prospective, retrospective and ambispective cohort studies), and case-control studies; (ⅳ) published in English; (ⅴ) results reporting adjusted measures of association (e.g., hazard ratio, risk ratio, and odds ratio) and their 95% confidence intervals (CIs). We excluded studies that included children, adolescents or pregnant women; studies that measured adverse events like narcolepsy or Guillain-Barré Syndrome after taking influenza vaccination; as well as case series (including self-controlled case series), case reports, reviews, and commentaries. Additionally, studies with incomplete data or duplicate publications were excluded. Two investigators (YYC and XXC) extracted data independently, and any disagreement was resolved by consensus or consultation with a third author (ZC). For each study, we collected the first author, journal, year of publication, study design, sample size, population demographics (including study region/country, number of males, and mean age or age range), the number of vaccinated subjects, outcomes, and fully adjusted measures of association with the corresponding 95% CIs. The Newcastle-Ottawa Scale (NOS) was designed for the evaluation of case-control and cohort studies (http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp). The quality of each study was graded as good, fair, or poor. To be rated as good, studies needed to meet all the criteria. A study was rated as poor when one or more domains were assessed as having a serious flaw. Studies that met some but not all of the criteria were rated as fair quality. Trail quality was determined as high quality by the Cochrane criteria if at least the first 3 criteria were accounted for, or otherwise of uncertain risk of material bias. Any disagreements or discrepancies regarding study selection, data extraction, and quality assessment were resolved by consensus. The Cochrane Collaboration was employed to evaluate the quality of each RCT (Higgins et al., 2011) . Outcomes measures for this meta-analysis included overall or composite cardiovascular outcomes and respiratory diseases as well as all-cause mortality. According to the disease outcome extracted from the original studies, the cardiovascular outcomes were further evaluated as individual conditions including stroke, myocardial infarction, ACS, heart failure, ischemic heart disease (IHD), major adverse cardiovascular events (MACEs), cardiovascular mortality, and unspecific heart disease. Similarly, respiratory outcomes were further evaluated as individual conditions, such as COPD, asthma, pneumonia, respiratory failure, respiratory infection, respiratory mortality, and unspecific respiratory disease. We used a random-effects model to estimate the effect of the influenza vaccination. For each outcome measure of interest, we pooled the confounder-adjusted HR/OR/RR and used the Cochran's Q chi-square test and I 2 statistic to assess the heterogeneity. Subgroup analyses and sensitivity analyses were performed to assess the associations found by selected studies with risks for cardiovascular diseases, respiratory diseases, and all-cause mortality, including age, sex, seasonality, pre-exiting specific diseases (e.g., cardiovascular diseases, chronic kidney, COPD, etc.), and region/country. Finally, a funnel plot and Egger's rank were used to evaluate the publication bias. All statistical procedures used a two-sided significance level of 0.05 and were conducted by Stata v.15.0. Figure 1 shows a flow diagram for the identification of studies included in this meta-analysis. First, our initial search yielded a total of 53,830 articles, 33,560 articles were included after the removal of duplicates. After screening the titles and abstracts, 33,078 records were excluded because the studies did not meet the selection criteria (e.g., no related outcome [n = 14,657], influenza, not vaccination [n = 11,895], vaccination not our aim [n = 4834], comment/reply/letter [n = 284], subjects not human [n = 205] , and meta-analysis [n = 1203]. Full-text articles were assessed for eligibility, 408 records were excluded because they included children or pregnant women [n = 53], did not involve influenza vaccination [n = 80], were conference abstracts [n = 30], or presented outcomes not related to our aim [n = 245] . Finally, we were left with 74 articles (including 75 studies) relevant for our meta-analysis. Among them, 47 were observational cohort studies, 22 were case-control studies, and 6 were RCTs. Characteristics of included studies and quality assessment Table 1 shows the details of the included articles. These articles were published between 1999 and 2018. The sample size of the included studies ranges from 60 to 2,244,594 participants. Among the included studies, one study was performed in the Europe, two were multi-national, and others were conducted in individual countries or regions. Among the latter, eleven were in the United States, three in Argentina, two in Canada, two in France, one in Germany, three in China/Hong Kong, three in Israel, one in Italy, three in Japan, three in the Netherlands, two in Poland, one in Saudi Arabia, seven in Spain, two in Sweden, twenty in China/Taiwan, two in Thailand, one in Turkey, and five in the United Kingdom. Some of these studies [n = 63] examined mainly outcomes related to cardiovascular diseases, such as stroke, myocardial infarction, ACS, heart failure, IHD, MACEs, cardiovascular mortality, and heart disease. Others mainly examined all-cause mortality [n = 43] or respiratory diseases [n = 34] including COPD, asthma, pneumonia, respiratory failure, respiratory infection, respiratory mortality, and respiratory disease. Of the 47 cohort studies, 23 were good quality, 19 were fair quality and 5 were poor quality; of the 22 case-control studies, 8 were good quality, 11 were fair quality and 3 were poor quality (details in Supplement Table A) . Influenza vaccination was associated with lower risk of adverse cardiovascular outcomes overall, with a relative risk of 0.74 (95% CI = 0.70-0.78; Table 2 and Figure 2 ). When stratified by specific cardiovascular conditions, the results showed that influenza vaccination was associated with reduced risk of stroke (RR = 0.80, 95% CI = 0.72-0.88), myocardial infarction (RR = 0.81, 95% CI = 0.76-0.86), ACS (RR = 0.44, 95% CI = 0.32-0.60), heart failure (RR = 0.60, 95% CI = 0.44-0.83), IHD (RR = 0.83, 95% CI = 0.77-0.90), MACEs (RR = 0.71, 95% CI = 0.62-0.82), and cardiovascular mortality (RR = 0.78, 95% CI = 0.65-0.94). In the subgroup analyses, most associations between influenza vaccination and cardiovascular risk reduction remained robust, while some were not significant. There were significant differences in the subgroup analyses according to the presence or absence of pre-existing specific diseases. Individuals with pre-existing diseases had a lower risk of about 0.62 (95% CI = 0.54-0.72), while individuals without them had a risk of about 0.83 (95% CI = 0.80-0.86; Table 3 Influenza vaccination was also associated with lower risk of adverse respiratory outcomes overall, with a relative risk of (RR = 0.82, 95% CI = 0.75-0.91; Table 2 and Figure 3 ). Regarding specific respiratory diseases, there were no statistically significant differences for COPD (RR = 0.82, 95% CI = 0.47-1.43), unspecific respiratory diseases (RR = 1.00, 95% CI = 0.90-1.11), respiratory failure (RR = 0.62, 95% CI = 0.38-1.00), or respiratory infections (RR = 0.95, 95% CI = 0.82-1.09). In contrast, there was a statistically significant reduction in pneumonia and respiratory mortality in those who received the influenza vaccination, with relative risks of 0.79 (95% CI = 0.65-0.95) and 0.79 (95% CI = 0.67-0.92), respectively (Figure 3 ). In the subgroup analysis according to age, the results showed that in the group aged over 65, influenza vaccination reduced the risk of respiratory diseases (RR = 0.86, 95% CI = 0.77-0.96), while in the group younger than 65, influenza vaccination had no significant relationship with the risk of respiratory diseases (RR = 0.92, 95% CI = 0.70-1.22; Table 3 ). We have identified 43 studies that examined the association of influenza vaccination with all-cause mortality. The pooled estimates from these studies showed a significant risk of all-cause mortality for vaccinated compared with unvaccinated individuals (RR = 0.57, 95%CI = 0.51-0.63; Table 3 and Figure 4 ). In the subgroup analyses, except in Japan, the association of influenza vaccination with all-cause mortality remained statistically significant (Table 3) . We conducted funnel plot analysis to check for potential publication bias, and the funnel plot was generally symmetric, indicating the absence of publication bias. This was further confirmed by a non-significant Egger's test for respiratory diseases, P = 0.971 and all-cause mortality, P = 0.235, except for that for cardiovascular outcomes, P = 0.013. We did sensitivity analysis excluding any trial from the pooled result. Results for the primary end point were similar when after removal of any trial from the pooled result (details in Supplement Table B ). This meta-analysis included large cohort and case-control studies as well as RCTs evaluating potential impact of influenza vaccination on severe cardiovascular and respiratory outcomes and all-cause mortality. Our results indicated that influenza vaccination had protective effects against morbidity and mortality of cardiovascular diseases (RR = 0.74, 95% CI = 0.70-0.78) and respiratory diseases (RR = 0.82, 95% CI = 0.75-0.91) as well as all-cause mortality (RR = 0.57, 95% CI = 0.51-0.63). Subgroup analyses showed that those effects of influenza vaccination were evident in the general population as well as in older adults and those with pre-existing specific diseases. The results on composite and specific cardiovascular adverse outcomes are consistent with two meta-analyses of RCTs that demonstrate significant association between influenza vaccination and a lower risk of major adverse cardiovascular events (Clar et al., 2015; Udell et al., 2013) , with a more pronounced effect in high-risk patients with recent coronary artery disease (Udell et al., 2013) . In patients with heart failure, influenza vaccination in the previous year has been shown to reduce the risk of mortality and hospitalization (Fukuta et al., 2019; Poudel et al., 2019; Rodrigues et al., 2020) . Influenza vaccination is also reported to reduce the risk of stroke (Lee et al., 2017; Smeeth et al., 2004; Tsivgoulis et al., 2018) . The underlying mechanisms for the observed protective effects of influenza vaccination against cardiovascular adverse events (and all-cause mortality) are likely complex and yet to be elucidated. However, several hypotheses have been proposed. First, respiratory infections including influenza can acutely increase cardiac and pulmonary workload and burden and, thus, trigger acute cardiovascular events, particularly in individuals with existing clinical or subclinical atherosclerosis or coronary artery disease. As such, by virtue of infection prevention, influenza vaccination provides cardiovascular protection. While this is a plausible mechanism, it cannot account for the effect size of cardiovascular protective effects from influenza vaccination, particularly during mild influenza seasons. Immune modulation on chronic inflammation, i.e., aforementioned age-related CLIP or inflammaging, has also been proposed as an attractive underlying mechanism. This is because age-related CLIP or inflammaging is known to play an important role in the development of atherosclerosis, coronary artery disease, and stroke (Chen et al., 2019; Elkind, 2009; Ferrucci and Fabbri, 2018) . Acutely, influenza infection can cause local and systemic inflammatory response (Madjid et al., 2007) that can adversely impact plaque stability, leading to plaque rupture and acute cardiovascular events (Barnett, 2019) . Therefore, annual influenza vaccination may prevent or delay the development or progression of atherosclerosis through its immune modulation of age-related CLIP or inflammaging for the long term and prevent adverse cardiovascular events acutely through its regulation on influenza-induced inflammatory response. By extension of the latter, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes acute systemic inflammatory response or "cytokine storm" in severe COVID-19 (Moore and June, 2020) . Whether influenza vaccination could regulate such cytokine storm and mitigate severe COVID-19 deserves further investigation. In fact, the existing Bacille Calmette-Guérin (BCG) vaccine that is not specific to SARS-CoV-2 is currently in clinical trial evaluating its potential protection against COVID-19 (Curtis et al., 2020) . Finally, regulation of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-Fn14 pathway has been proposed as a novel molecular mechanism mediating cardiovascular protective effects of influenza vaccination (Keshtkar-Jahromi et al., 2018) . TWEAK-Fn14 pathway is considered as a critical "immune switch" (Burkly et al., 2011) . Studies both in humans and in animal models suggest that activation of TWEAK-Fn14 pathway play an important role in contributing to cardiovascular diseases and their severity (Chorianopoulos et al., 2010; Novoyatleva et al., 2013; Sastre et al., 2014) . Keshtkar-Jahromi and colleagues have shown that influenza vaccination significantly reduced circulating TWEAK levels in older adults, providing initial evidence supportive of this molecular mechanism that deserves further investigation (Keshtkar-Jahromi et al., 2018) . Associations of influenza vaccination with reduced risk of overall respiratory adverse outcomes and specific respiratory conditions are not as robust or broad as those with cardiovascular outcomes and conditions. Significant protective effects of influenza vaccination against overall respiratory outcomes, pneumonia and respiratory mortality are most likely secondary to its prevention of influenza infection. These results are consistent with the data reported by Yin et al that compared to placebo or no vaccination, dual influenza and pneumococcal vaccinations (1-odds ratio) prevents influenza by 35% and pneumonia by 29%; it reduces hospitalization by 18% and respiratory mortality by 38% (Yin et al., 2018) . Our results indicate no significant associations of influenza vaccination with risk reduction of other respiratory infections or diseases after excluding influenza infection, nor with that of COPD and respiratory failure. Factors contributing to the development and worsening of COPD and respiratory failure are complex, and effects of influenza vaccination on these conditions require further investigation. Data from the subgroup analyses indicate similar or slightly more robust protective effects of influenza vaccination in older adults compared to those younger than 65 years of age. This finding has significant clinical implication because of high prevalence of cardiovascular and pulmonary diseases in older adults. At the same time, this is somewhat counter intuitive, as many studies have shown reduced effectiveness of influenza vaccination in prevention of influenza infection in older adults (Gross et al., 1995; Hak et al., 2002; Nichol et al., 2007; Vu et al., 2002) . One likely reason is the immune modulating effects of influenza vaccination on age-related CLIP or inflammaging as described above. It may also be explained by high disease burden of cardiovascular and pulmonary conditions in older adults. Sex difference identified in this study is consistent with evidence on sex differences in immune responses to influenza vaccination reported previously (Fink et al., 2018; Fink and Klein, 2015; Klein et al., 2015) and is currently under active research of our group. Another important point about our subgroup analyses worthwhile mentioning here is that protective effects of influenza vaccination against cardiovascular and respiratory conditions as well as all-cause mortality are also evident in individuals with pre-existing diseases, emphasizing generalizability of our findings. In addition, with very few exceptions, such protective effects are present across different countries and regions. Most previous studies have focused on one specific outcome or patient population with a specific disease. A major strength of the present study is that we used influenza vaccination as our keyword and did not limit the outcomes, enabling use to increase the chance of detecting all outcomes. Our study has several limitations. First, heterogeneity was evident within individual outcome endpoints. We only performed subgroup analyses according to sex, age, study design, study country or region, and pre-existing specific disease. Second, given the lack of more detailed study parameters such as the type or dose of influenza vaccine administered, we were unable to examine other factors that can potentially account for the observed heterogeneity. Third we extracted the adjusted estimates (OR/RR/HR), but were unable to convert them into a unified format. Finally, as the funnel plot revealed an apparent asymmetry, there are potential bias, language bias, and potential risk of inflated estimates by a flawed methodological design in smaller studies and/or a lack of publication of small trials with opposite results. Despite of these limitations, findings from this comprehensive and in-depth meta-analysis suggest significant protective effects of influenza vaccination against cardiovascular and respiratory adverse outcomes as well as all-cause mortality. They also provide strong evidence to support and promote influenza vaccination coverage. In the US, influenza vaccination coverage in the general adult population remains suboptimal (Lu et al., 2019) and the National Institute of Allergy and Infectious Disease (NIAID) of NIH has launch the universal influenza vaccine initiative (Paules et al., 2017) . The situation in China is even more concerning as a national survey conducted from 2004 to 2014 reported vaccination coverage in China as low as 1.5%-2% (Yang et al., 2016) . Therefore, efforts for promoting vaccination coverage (Li and Leng, 2020) and evidence supporting such efforts have profound public health implications, particularly in the era of the ongoing COVID-19 pandemic. This meta-analysis provides comprehensive summary and synthesis of existing evidence supportive of significant associations between influenza vaccination and reduced risks for cardiovascular diseases and respiratory adverse outcomes as well as all-cause mortality. These beneficial associations are evident not only in older adults and individuals with pre-existing conditions, but also in the general adult population across different countries and regions, indicating the generalizability. The findings also point out the need for more RCTs to further evaluate and confirm the beneficial health effects of influenza vaccination on respiratory health and other important health outcomes beyond influenza prevention. They also provide supportive evidence for promoting influenza vaccination coverage with significant public health implications, particularly in the era of the ongoing COVID-19 pandemic. J o u r n a l P r e -p r o o f Funding This study was funded by the National Natural Science Foundation of China (NSFC, Grant No. 71910107004, 91746205) to YGW, National Institutes of Health (NIH) of USA (R01 AI108907, R21 AG059742, and U54 AG062333) to SXL, Irma and Paul Milstein Program for Senior Health fellowship award from Milstein Medical Asian American Partnership (MMAAP) Foundation of USA (www.mmaapf.org) to CJW, and funding from Irma and Paul Milstein Program for Senior Health, MMAAP Foundation of USA (www.mmaapf.org) to SXL. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With Influenza Acute myocardial infarction Effects of annual influenza vaccination on mortality in patients with heart failure Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes Mortality of dialysis patients according to influenza and pneumococcal vaccination status. American journal of kidney diseases : the official journal of the National Kidney Foundation TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses Influenza vaccination and all-cause mortality in community-dwelling elderly in Ontario, Canada, a cohort study Enhanced Estimates of the Influenza Vaccination Effect in Preventing Mortality: A Prospective Cohort Study Efficacy of trivalent seasonal influenza vaccination in reducing mortality and hospitalization in Chinese nursing home older adults Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1) Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan--a representative population-based comparative study Influenza Vaccination is Associated with Lower Risk of Acute Coronary Syndrome in Elderly Patients with Chronic Kidney Disease Influenza vaccination may lead to reduction of hospitalization for heart failure in elderly patients with chronic obstructive pulmonary disease Chronic Low-grade Inflammatory Phenotype (CLIP) and Senescent Immune Dysregulation Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI -a report from FLUCAD study Influenza vaccines for preventing cardiovascular disease. The Cochrane database of systematic reviews Considering BCG vaccination to reduce the impact of COVID-19 Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease Inflammatory markers and stroke Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Influenza Vaccination Reduces Hospitalization for Heart Failure in Elderly Patients with Chronic Kidney Disease: A Population-Based Cohort Study Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty Biological sex affects vaccine efficacy and protection against influenza in mice Sex and Gender Impact Immune Responses to Vaccines Among the Elderly Inflamm-aging. An evolutionary perspective on immunosenescence The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial Influenza vaccination is associated with a reduced risk of stroke Prevention and Control of Seasonal Influenza with Vaccines The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations Influenza vaccination and risk of incident myocardial infarction Effects of previous influenza vaccination on subsequent readmission and mortality in elderly patients hospitalized with pneumonia Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes The Cochrane Collaboration's tool for assessing risk of bias in randomised trials A Matched Influenza Vaccine Strain Was Effective in Reducing the Risk of Acute Myocardial Infarction in Elderly Persons: A Population-Based Study Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population-based case-cohort study Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study Influenza vaccination and major adverse vascular events in high-risk patients A case-control study of elderly patients with acute respiratory illness: effect of influenza vaccination on admission Influenza vaccination might reduce the risk of ischemic stroke in patients with atrial fibrillation: A population-based cohort study Influence of influenza vaccination on recurrent hospitalization in patients with heart failure Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults Sex-based differences in immune function and responses to vaccination Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009-2010 season in Japan: A case-control study Influenza vaccine and survival in acute heart failure Influenza vaccine for chronic obstructive pulmonary disease (COPD). The Cochrane database of systematic reviews 6 Effects of influenza vaccination on mortality among frail, community-living elderly patients: an observational study Association between influenza vaccination and reduced risk of brain infarction Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis The impact of influenza vaccination on hospitalizations and mortality among frail older people Influenza immunization among Chinese seniors: Urgent calling for improving vaccination coverage, education, and research. Aging medicine Association of influenza vaccination and reduced risk of stroke hospitalization among the elderly: a population-based case-control study Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: a nationwide population-based study Effect of Influenza Vaccination Against Postoperative Pneumonia and Mortality for Geriatric Patients Receiving Major Surgery: A Nationwide Matched Study Seasonal Influenza Vaccination Coverage Trends Among Adult Populations Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study Influenza and pneumococcal vaccinations fail to prevent myocardial infarction Cytokine release syndrome in severe COVID-19 Association of influenza vaccination and reduced risk of recurrent myocardial infarction Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly Effectiveness of influenza vaccine in the community-dwelling elderly The twilight of immunity: emerging concepts in aging of the immune system TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy Influenza (Seasonal) Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. The European respiratory journal The Pathway to a Universal Influenza Vaccine Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome Chronic bronchitis and acute infections as new risk factors for ischemic stroke and the lack of protection offered by the influenza vaccination Influenza and pneumococcal vaccination in older adults living in nursing home: a survival analysis on the shelter study The Effect of Influenza Vaccination on Mortality and Risk of Hospitalization in Patients With Heart Failure: A Systematic Review and Meta-analysis. Open forum infectious diseases 6 Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly Economic burden of seasonal influenza in the United States The comparison of influenza vaccine efficacy on respiratory disease among Iranian pilgrims in the 2003 and 2004 seasons Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years Estimating the burden of SARS-CoV-2 in France Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice Influenza vaccination: reduction in hospitalizations and death rates among members of "Maccabi Healthcare Services" during the 2000-2001 influenza season Impact of National Influenza Vaccine Campaign on Respiratory Illness in Thailand Impact of influenza vaccination on seasonal mortality in the US elderly population Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-matched case control study Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study Influenza vaccination and the risk of primary cardiac arrest Risk of myocardial infarction and stroke after acute infection or vaccination Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection: A population-based analysis Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly patients with chronic obstructive pulmonary disease: a population-based cohort study Estimates of US influenza-associated deaths made using four different methods The effect of influenza vaccination on the incidence of chronic obstructive pulmonary disease exacerbations in the immediate postvaccination period The relationship between influenza vaccination and outpatient visits for upper respiratory infection by the elderly in Taiwan The association of adult vaccination with the risk of cerebrovascular ischemia: A systematic review and meta-analysis Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis Effects of annual influenza vaccination on winter mortality in elderly people with chronic pulmonary disease Annual revaccination against influenza and mortality risk in community-dwelling elderly persons Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community Impact of influenza vaccination on major cause-specific mortality Seasonal influenza vaccination is associated with reduced morbidity and mortality in peritoneal dialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis Hypoalbuminemia, influenza vaccination and other factors related to the development of pneumonia acquired outside hospitals in southern Japan: A case-control study Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis Effectiveness and safety of dual influenza and pneumococcal vaccination versus separate administration or no vaccination in older adults: a meta-analysis The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study We declare no competing interests.